Amgen Company Leadership
AMGN Stock | USD 274.73 1.19 0.44% |
About 67% of Amgen's corporate insiders are selling. The analysis of the overall insider sentiment regarding Amgen Inc suggests that many insiders are alarmed. Amgen employs about 26.7 K people. The company is managed by 44 executives with a total tenure of roughly 397 years, averaging almost 9.0 years of service per executive, having 606.82 employees per reported executive.
Robert Bradway Chairman Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee |
David Reese President Executive Vice President - Research and Development |
Amgen's Insider Buying Vs Selling
33
Selling | Buying |
Latest Trades
2024-01-23 | Kathy E. Manning | Acquired @ 309.91 | |||
2024-01-19 | Tommy Tuberville | Disposed @ 307.81 | |||
2024-01-02 | Michael C. Burgess | Disposed @ 297.39 | |||
2023-12-04 | Nancy A Grygiel | Disposed 2096 @ 273.03 | View | ||
2023-11-08 | Jonathan P Graham | Disposed 10000 @ 272.81 | View | ||
2023-10-24 | Greg Stanton | Disposed @ 276.12 | |||
2023-09-26 | Greg Stanton | Acquired @ 269.04 | |||
2023-09-19 | Amgen Inc | Acquired 1764705 @ 17 | View | ||
2023-08-10 | Murdo Gordon | Disposed 9558 @ 262.43 | View |
Monitoring Amgen's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Amgen's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Amgen Inc. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Amgen's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Amgen |
Amgen's latest congressional trading
Congressional trading in companies like Amgen Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Amgen by those in governmental positions are based on the same information available to the general public.
2024-01-19 | Senator Thomas H Tuberville | Acquired $15K to $50K | Verify | ||
2023-09-26 | Representative Greg Stanton | Acquired Under $15K | Verify | ||
2023-06-12 | Senator Shelley M Capito | Acquired Under $15K | Verify | ||
2022-10-06 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
2022-09-26 | Representative Earl Blumenauer | Acquired Under $15K | Verify | ||
2022-02-22 | Representative Marjorie Taylor Greene | Acquired Under $15K | Verify | ||
2021-03-04 | Representative Carol Devine Miller | Acquired $15K to $50K | Verify | ||
2021-02-16 | Representative Peter Meijer | Acquired Under $15K | Verify | ||
2021-02-05 | Representative Kurt Schrader | Acquired Under $15K | Verify | ||
2020-11-05 | Senator Bill Cassidy | Acquired Under $15K | Verify | ||
2020-04-07 | Senator Kelly Loeffler | Acquired $15K to $50K | Verify | ||
2020-02-20 | Representative Mikie Sherrill | Disposed Under $15K | Verify | ||
2019-09-19 | Representative Bill Flores | Acquired Under $15K | Verify | ||
2019-08-28 | Representative Richard W. Allen | Acquired $15K to $50K | Verify | ||
2019-02-04 | Senator Jack Reed | Acquired Under $15K | Verify | ||
2018-10-05 | Representative Gary Palmer | Acquired Under $15K | Verify | ||
2018-04-24 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
2017-05-30 | Senator James M. Inhofe | Acquired $50K to $100K | Verify | ||
2017-01-20 | Senator John Hoeven | Acquired $50K to $100K | Verify | ||
2016-04-12 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify |
Amgen Management Team Effectiveness
The company has return on total asset (ROA) of 0.0629 % which means that it generated a profit of $0.0629 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.3579 %, meaning that it created $1.3579 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Amgen's Return On Assets are very stable compared to the past year. As of the 24th of April 2024, Return On Equity is likely to grow to 1.13, while Return On Tangible Assets are likely to drop 0.12. At this time, Amgen's Return On Assets are very stable compared to the past year. As of the 24th of April 2024, Asset Turnover is likely to grow to 0.51, while Other Current Assets are likely to drop about 266.9 M.As of the 24th of April 2024, Common Stock Shares Outstanding is likely to grow to about 759.2 M, while Net Income Applicable To Common Shares is likely to drop about 5 B.
Amgen Workforce Comparison
Amgen Inc is rated below average in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 469,270. Amgen holds roughly 26,700 in number of employees claiming about 6% of equities under Health Care industry.
Amgen Profit Margins
The company has Profit Margin (PM) of 0.24 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.08 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.08.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.65 | 0.7002 |
|
| |||||
Net Profit Margin | 0.18 | 0.2383 |
|
| |||||
Pretax Profit Margin | 0.25 | 0.2786 |
|
| |||||
Return On Assets | 0.12 | 0.0691 |
|
| |||||
Return On Equity | 1.13 | 1.0778 |
|
|
Amgen Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amgen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amgen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Amgen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 1.2 | 12 | 10 | 128,172 | 52,169 |
2023-12-01 | 0.2727 | 3 | 11 | 778.18 | 18,395 |
2023-09-01 | 1.0 | 3 | 3 | 402.61 | 10,687 |
2023-06-01 | 1.0938 | 35 | 32 | 343,194 | 24,751 |
2023-03-01 | 1.0 | 10 | 10 | 69,837 | 33,994 |
2022-12-01 | 0.3 | 3 | 10 | 615.62 | 8,687 |
2022-09-01 | 0.5 | 4 | 8 | 20,896 | 55,437 |
2022-06-01 | 0.8919 | 33 | 37 | 472,935 | 107,264 |
2022-03-01 | 0.9 | 9 | 10 | 77,529 | 36,444 |
2021-12-01 | 1.2 | 6 | 5 | 3,728 | 13,381 |
2021-09-01 | 1.5 | 3 | 2 | 1,390 | 0.00 |
2021-06-01 | 0.9459 | 35 | 37 | 375,777 | 40,250 |
2021-03-01 | 0.6818 | 15 | 22 | 165,980 | 186,952 |
2020-12-01 | 0.6667 | 2 | 3 | 1,594 | 8,644 |
2020-09-01 | 0.625 | 5 | 8 | 10,823 | 6,705 |
2020-06-01 | 0.9189 | 34 | 37 | 459,197 | 205,597 |
2020-03-01 | 0.6923 | 9 | 13 | 100,324 | 61,126 |
2019-12-01 | 0.6667 | 8 | 12 | 30,013 | 47,893 |
2019-09-01 | 0.5385 | 7 | 13 | 14,877 | 37,554 |
2019-06-01 | 1.2222 | 33 | 27 | 419,231 | 40,214 |
2019-03-01 | 0.6111 | 11 | 18 | 96,210 | 56,365 |
2018-12-01 | 1.0 | 7 | 7 | 75,562 | 54,163 |
2018-09-01 | 0.5714 | 4 | 7 | 3,919 | 21,452 |
2018-06-01 | 1.5 | 33 | 22 | 1,480,178 | 2,297,615 |
2018-03-01 | 0.3478 | 8 | 23 | 110,457 | 66,595 |
2017-06-01 | 3.0 | 36 | 12 | 441,529 | 10,778 |
2017-03-01 | 0.3333 | 9 | 27 | 158,860 | 94,677 |
2016-12-01 | 0.25 | 1 | 4 | 355.00 | 3,152 |
2016-09-01 | 0.1429 | 1 | 7 | 5,000 | 24,198 |
2016-06-01 | 1.8947 | 36 | 19 | 425,332 | 69,131 |
2016-03-01 | 0.4706 | 16 | 34 | 425,541 | 361,181 |
2015-09-01 | 0.8333 | 5 | 6 | 57,219 | 28,145 |
2015-06-01 | 0.5806 | 18 | 31 | 38,722 | 102,954 |
2015-03-01 | 0.675 | 27 | 40 | 551,241 | 401,723 |
2014-12-01 | 0.0833 | 1 | 12 | 309.00 | 43,542 |
2014-09-01 | 0.4615 | 6 | 13 | 86,163 | 73,354 |
2014-06-01 | 0.3488 | 15 | 43 | 23,471 | 34,336 |
2014-03-01 | 0.9615 | 25 | 26 | 265,182 | 248,416 |
2013-12-01 | 1.0 | 3 | 3 | 14,785 | 13,421 |
2013-09-01 | 0.4 | 2 | 5 | 36,000 | 59,492 |
2013-06-01 | 0.4667 | 28 | 60 | 94,492 | 241,160 |
2013-03-01 | 1.2 | 18 | 15 | 172,646 | 82,420 |
2012-12-01 | 0.5 | 6 | 12 | 76,420 | 148,271 |
2012-09-01 | 0.6604 | 35 | 53 | 849,170 | 1,364,514 |
2012-06-01 | 0.6964 | 39 | 56 | 203,732 | 270,446 |
2012-03-01 | 0.75 | 36 | 48 | 522,700 | 839,960 |
2011-12-01 | 1.0 | 7 | 7 | 32,114 | 82,461 |
2011-09-01 | 0.9 | 9 | 10 | 25,651 | 67,079 |
2011-06-01 | 1.1515 | 38 | 33 | 414,048 | 76,095 |
2011-03-01 | 0.8889 | 8 | 9 | 67,836 | 39,746 |
2010-12-01 | 1.0 | 4 | 4 | 300,900 | 16,050 |
2010-09-01 | 0.1667 | 2 | 12 | 21,583 | 50,197 |
2010-06-01 | 1.2903 | 40 | 31 | 654,123 | 40,106 |
2010-03-01 | 0.5652 | 13 | 23 | 105,580 | 120,656 |
2009-12-01 | 0.0588 | 1 | 17 | 800.00 | 23,705 |
2009-09-01 | 0.5 | 2 | 4 | 25,106 | 8,610 |
2009-06-01 | 1.4815 | 40 | 27 | 619,470 | 127,363 |
2009-03-01 | 0.0476 | 1 | 21 | 16,000 | 48,536 |
2008-12-01 | 0.1183 | 11 | 93 | 257,001 | 442,548 |
2008-09-01 | 0.1667 | 1 | 6 | 20,500 | 7,680 |
2008-06-01 | 1.1429 | 32 | 28 | 701,743 | 380,336 |
2007-12-01 | 1.5 | 3 | 2 | 34,634 | 36,908 |
2007-09-01 | 0.3333 | 1 | 3 | 25,000 | 51,340 |
2007-06-01 | 1.3 | 26 | 20 | 478,088 | 374,273 |
2006-12-01 | 0.1522 | 7 | 46 | 136,859 | 270,008 |
2006-06-01 | 0.2895 | 11 | 38 | 256,500 | 268,262 |
2006-03-01 | 0.2899 | 20 | 69 | 95,091 | 232,607 |
2005-12-01 | 0.1148 | 7 | 61 | 188,423 | 423,722 |
2005-09-01 | 0.2414 | 14 | 58 | 607,103 | 1,198,115 |
2005-06-01 | 0.2917 | 7 | 24 | 805,749 | 1,054,848 |
2005-03-01 | 1.0 | 28 | 28 | 1,525,261 | 1,411,655 |
2004-12-01 | 0.2222 | 6 | 27 | 159,198 | 478,397 |
2004-09-01 | 0.2308 | 6 | 26 | 81,572 | 523,297 |
2004-06-01 | 0.4286 | 9 | 21 | 21,000 | 129,787 |
2004-03-01 | 1.0 | 33 | 33 | 493,017 | 336,934 |
2003-12-01 | 0.0857 | 3 | 35 | 22,762 | 302,192 |
2003-09-01 | 0.5938 | 19 | 32 | 840,770 | 462,676 |
Amgen Notable Stakeholders
An Amgen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Amgen often face trade-offs trying to please all of them. Amgen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Amgen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert Bradway | Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee | Profile | |
David Reese | Executive Vice President - Research and Development | Profile | |
Brian McNamee | Executive Vice President - Full Potential Initiatives | Profile | |
Esteban Santos | Executive Vice President Operations | Profile | |
Jonathan Graham | Senior Vice President General Counsel, Secretary | Profile | |
Sean Harper | Executive Vice President - Research and Development | Profile | |
Stuart Tross | Senior Vice President - Human Resources | Profile | |
Murdo Gordon | Executive Vice President of Global Commercial Operations | Profile | |
Lori Johnston | Senior Vice President - Human Resources | Profile | |
Cynthia Patton | Senior Vice President Chief Compliance Officer | Profile | |
David Piacquad | Senior Vice President - Business Development | Profile | |
David Meline | CFO and Executive VP | Profile | |
Peter Griffith | Executive CFO | Profile | |
Madhavan Balachandran | Executive VP of Operations | Profile | |
Anthony Hooper | Executive VP of Global Commercial Operations | Profile | |
Frank Herringer | Independent Director | Profile | |
Francois Carbonnel | Independent Director | Profile | |
Rebecca Henderson | Independent Director | Profile | |
Sanders Williams | Independent Director | Profile | |
Vance Coffman | Lead Independent Director | Profile | |
Tyler Jacks | Independent Director | Profile | |
Gregory Garland | Independent Director | Profile | |
Charles Holley | Director | Profile | |
Ellen Kullman | Director | Profile | |
Frank Biondi | Independent Director | Profile | |
Ronald Sugar | Independent Director | Profile | |
Wanda Austin | Independent Director | Profile | |
Robert Eckert | Independent Director | Profile | |
Brian Druker | Independent Director | Profile | |
Greg Garland | Independent Director | Profile | |
Robert Williams | Independent Director | Profile | |
Judith Pelham | Independent Director | Profile | |
David Baltimore | Independent Director | Profile | |
Fred Hassan | Director | Profile | |
Linda Louie | VP Officer | Profile | |
James MD | Executive Officer | Profile | |
Nancy Grygiel | Senior Officer | Profile | |
Annette Such | Chief Accounting Officer | Profile | |
Mike Zahigian | Senior Officer | Profile | |
Arvind Sood | IR Contact Officer | Profile | |
Justin Claeys | Vice Relations | Profile | |
Matthew Busch | Chief Finance | Profile | |
Alan Russell | Vice Biologics | Profile | |
David MD | Executive Officer | Profile |
About Amgen Management Performance
The success or failure of an entity such as Amgen Inc often depends on how effective the management is. Amgen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Amgen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Amgen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.15 | 0.12 | |
Return On Capital Employed | 0.10 | 0.1 | |
Return On Assets | 0.07 | 0.12 | |
Return On Equity | 1.08 | 1.13 |
The data published in Amgen's official financial statements usually reflect Amgen's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Amgen Inc. For example, before you start analyzing numbers published by Amgen accountants, it's critical to develop an understanding of what Amgen's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Amgen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amgen's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Amgen's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Amgen Inc. Please utilize our Beneish M Score to check the likelihood of Amgen's management manipulating its earnings.
Amgen Workforce Analysis
Traditionally, organizations such as Amgen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Amgen within its industry.Amgen Manpower Efficiency
Return on Amgen Manpower
Revenue Per Employee | 1.1M | |
Revenue Per Executive | 640.7M | |
Net Income Per Employee | 251.6K | |
Net Income Per Executive | 152.7M | |
Working Capital Per Employee | 447.2K | |
Working Capital Per Executive | 271.4M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Amgen Inc information on this page should be used as a complementary analysis to other Amgen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Amgen Stock analysis
When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Amgen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.52) | Dividend Share 8.52 | Earnings Share 12.5 | Revenue Per Share 52.692 | Quarterly Revenue Growth 0.198 |
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.